These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31616148)

  • 21. Efficacy and safety of aripiprazole once-monthly versus oral aripiprazole in Chinese patients with acute schizophrenia: a multicenter, randomized, double-blind, non-inferiority study.
    Xiao L; Zhao Q; Li AN; Sun J; Wu B; Wang L; Zhang H; Zhang R; Li K; Xu X; Liu T; Zhang W; Xie S; Xu X; Tan Y; Zhang K; Zhang H; Guan N; Xian M; Uki M; Wang G
    Psychopharmacology (Berl); 2022 Jan; 239(1):243-251. PubMed ID: 34989824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study.
    Kane JM; Peters-Strickland T; Baker RA; Hertel P; Eramo A; Jin N; Perry PP; Gara M; McQuade RD; Carson WH; Sanchez R
    J Clin Psychiatry; 2014 Nov; 75(11):1254-60. PubMed ID: 25188501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.
    Keck PE; Calabrese JR; McIntyre RS; McQuade RD; Carson WH; Eudicone JM; Carlson BX; Marcus RN; Sanchez R;
    J Clin Psychiatry; 2007 Oct; 68(10):1480-91. PubMed ID: 17960961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initiation of aripiprazole once-monthly in patients with schizophrenia.
    Raoufinia A; Baker RA; Eramo A; Nylander AG; Landsberg W; Kostic D; Larsen F
    Curr Med Res Opin; 2015 Mar; 31(3):583-92. PubMed ID: 25586294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of aripiprazole lauroxil once-monthly versus aripiprazole once-monthly long-acting injectable formulations in patients with acute symptoms of schizophrenia: an indirect comparison of two double-blind placebo-controlled studies.
    Cameron C; Zummo J; Desai D; Drake C; Hutton B; Kotb A; Weiden PJ
    Curr Med Res Opin; 2018 Apr; 34(4):725-733. PubMed ID: 29179595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder.
    Yatham LN
    J Affect Disord; 2011 Jan; 128 Suppl 1():S21-8. PubMed ID: 21220077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder.
    Banaschewski T; Johnson M; Lecendreux M; Zuddas A; Adeyi B; Hodgkins P; Squires LA; Coghill DR
    CNS Drugs; 2014 Dec; 28(12):1191-203. PubMed ID: 25139785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies.
    Fleischhacker WW; Baker RA; Eramo A; Sanchez R; Tsai LF; Peters-Strickland T; Perry PP; McQuade RD; Johnson BR; Carson WH; Kane JM
    Schizophr Res; 2014 Nov; 159(2-3):415-20. PubMed ID: 25281992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data.
    Yan T; Greene M; Chang E; Hartry A; Touya M; Broder MS
    Adv Ther; 2018 Oct; 35(10):1612-1625. PubMed ID: 30206822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aripiprazole once-monthly long-acting injectable for the treatment of schizophrenia.
    Potkin SG; Preda A
    Expert Opin Pharmacother; 2016; 17(3):395-407. PubMed ID: 26864352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of cariprazine on function in patients with bipolar depression: a 
    Vieta E; Calabrese JR; Whelan J; Tohen M; Earley WR
    Curr Med Res Opin; 2021 Sep; 37(9):1635-1643. PubMed ID: 34034612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic evaluation of the aripiprazole (once-monthly) injection for the treatment of bipolar disorder.
    Hebbrecht K; Morrens M; Neels H; Roosens L; Sabbe BGC
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):999-1005. PubMed ID: 30141352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment with aripiprazole once-monthly injectable formulation is effective in improving symptoms and global functioning in schizophrenia with and without comorbid substance use - a post hoc analysis of the ReLiAM study.
    Margolese HC; Boucher M; Therrien F; Clerzius G
    BMC Psychiatry; 2022 Dec; 22(1):773. PubMed ID: 36482352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.
    Naber D; Baker RA; Eramo A; Forray C; Hansen K; Sapin C; Peters-Strickland T; Nylander AG; Hertel P; Nitschky Schmidt S; Loze JY; Potkin SG
    Schizophr Res; 2018 Feb; 192():205-210. PubMed ID: 28433498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aripiprazole for the maintenance treatment of bipolar I disorder: A review.
    McIntyre RS
    Clin Ther; 2010; 32 Suppl 1():S32-8. PubMed ID: 20152551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis.
    Kane JM; Zhao C; Johnson BR; Baker RA; Eramo A; McQuade RD; Duca AR; Sanchez R; Peters-Strickland T
    J Med Econ; 2015 Feb; 18(2):145-54. PubMed ID: 25347448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study.
    Findling RL; Correll CU; Nyilas M; Forbes RA; McQuade RD; Jin N; Ivanova S; Mankoski R; Carson WH; Carlson GA
    Bipolar Disord; 2013 Mar; 15(2):138-49. PubMed ID: 23437959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
    Tempest M; Sapin C; Beillat M; Robinson P; Treur M
    J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.
    Vieta E; Owen R; Baudelet C; McQuade RD; Sanchez R; Marcus RN
    Curr Med Res Opin; 2010 Jun; 26(6):1485-96. PubMed ID: 20429835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.